Start Preamble
AGENCY:
Drug Enforcement Administration, Justice.
ACTION:
Notice of application.
SUMMARY:
S&B Pharma, Inc., has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
DATES:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 26, 2021. Such persons may also file a written request for a hearing on the application on or before April 26, 2021.
ADDRESSES:
Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.
End Preamble
Start Supplemental Information
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR 1301.33(a), this is notice that on November 11, 2020, S&B Pharma, Inc., 405 South Motor Avenue, Azusa, California 91702-3232, applied to be registered as an bulk manufacturer of the following basic class(es) of controlled substance(s):
Controlled substance | Drug code | Schedule |
---|
Gamma Hydroxybutyric Acid | 7360 | I |
Tetrahydrocannabinols | 7370 | I |
Amphetamine | 1100 | II |
Methamphetamine | 1105 | II |
Lisdexamfetamine | 1205 | II |
Methylphenidate | 1724 | II |
Pentobarbital | 2270 | II |
4-Anilino-N-phenethyl-4-piperidine (ANPP) | 8333 | II |
Tapentadol | 9780 | II |
Fentanyl | 9801 | II |
The company plans to manufacture the listed controlled substances in bulk for use in product development and for commercial sales to its customers. In reference to drug code 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture both as synthetic substances. No other activity for these drug codes is authorized for this registration.
Start Signature
William T. McDermott,
Assistant Administrator.
End Signature
End Supplemental Information
[FR Doc. 2021-03837 Filed 2-24-21; 8:45 am]
BILLING CODE 4410-09-P
This document has a comment period that ends in 3 days. (04/26/2021) Submit a formal comment